Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Friday. They currently have a $50.00 price target on the biotechnology company’s stock.

The analysts wrote, “We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50.””

A number of other analysts have also recently weighed in on the company. ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. BidaskClub cut Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 19th. Finally, Zacks Investment Research cut Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $35.94.

Aclaris Therapeutics stock opened at $5.63 on Friday. Aclaris Therapeutics has a 1-year low of $5.49 and a 1-year high of $21.97. The firm has a market capitalization of $242.75 million, a price-to-earnings ratio of -2.25 and a beta of 1.24.

Several institutional investors and hedge funds have recently bought and sold shares of ACRS. Citigroup Inc. increased its position in shares of Aclaris Therapeutics by 3,200.0% during the fourth quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 3,872 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of Aclaris Therapeutics during the fourth quarter worth about $43,000. Legal & General Group Plc increased its position in shares of Aclaris Therapeutics by 64.1% during the fourth quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,536 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of Aclaris Therapeutics by 493.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,078 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 10,043 shares in the last quarter. Finally, American International Group Inc. increased its position in shares of Aclaris Therapeutics by 31.4% during the fourth quarter. American International Group Inc. now owns 23,307 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 5,575 shares in the last quarter. Institutional investors and hedge funds own 95.20% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Featured Article: Gross Domestic Product (GDP)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.